{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:04:44Z","timestamp":1784016284930,"version":"3.55.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100019713","name":"VA Pittsburgh Healthcare System","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck & Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017016","name":"Geriatric Research Education and Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017016","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jamda.2025.106028","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T17:08:16Z","timestamp":1766596096000},"page":"106028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Feasibility of Safe and Efficient Administration of COVID-19 Chemoprophylaxis to Nursing Home Residents"],"prefix":"10.1016","volume":"27","author":[{"given":"Amelia L.","family":"Milner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigid","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taissa A.","family":"Bej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oteshia","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Kowal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pruskowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5601-8996","authenticated-orcid":false,"given":"Robin L.P.","family":"Jump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2025.106028_bib1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/irv.12464","article-title":"Influenza in long-term care facilities","volume":"11","author":"Lansbury","year":"2017","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.jamda.2025.106028_bib2","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70008","article-title":"Burden of Respiratory Syncytial Virus (RSV) infection among adults in nursing and care homes: a systematic review","volume":"18","author":"Osei-Yeboah","year":"2024","journal-title":"Influenza Other Respir Viruses"},{"issue":"Supplement_1","key":"10.1016\/j.jamda.2025.106028_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae631.173","article-title":"572. The burden of RSV infections among nursing home residents, Monroe County, NY, October 2022 to April 2023","volume":"12","author":"Popham","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jamda.2025.106028_bib5","article-title":"Evaluation of influenza antiviral prophylaxis for long-term care residents: a systematic review and meta-analysis","author":"Hanula","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jamda.2025.106028_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15585\/mmwr.mm7315a3","article-title":"COVID-19 vaccination coverage, and rates of SARS-CoV-2 infection and COVID-19\u2013Associated hospitalization among residents in nursing homes \u2014 national healthcare safety network, United States, October 2023\u2013February 2024","volume":"73","author":"Franklin","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jamda.2025.106028_bib8","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/cid\/ciab715","article-title":"Pre-Hospital administration of remdesivir during a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) outbreak in a skilled nursing facility","volume":"74","author":"Dunay","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jamda.2025.106028_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.10887","article-title":"Clinical outcomes following treatment for COVID-19 with Nirmatrelvir\/Ritonavir and Molnupiravir among patients living in nursing homes","volume":"6","author":"Ma","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jamda.2025.106028_bib10","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1016\/j.jamda.2021.07.027","article-title":"Protecting nursing homes and long-term care facilities from COVID-19: a rapid review of international evidence","volume":"22","author":"Dykgraaf","year":"2021","journal-title":"J Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2025.106028_bib11","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa2309002","article-title":"Oral nirmatrelvir-ritonavir as postexposure prophylaxis for Covid-19","volume":"391","author":"Hammond","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jamda.2025.106028_bib12","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jinf.2023.08.016","article-title":"Molnupiravir for intra-household prevention of COVID-19: the MOVe-AHEAD randomized, placebo-controlled trial","volume":"87","author":"Alpizar","year":"2023","journal-title":"J Infect"},{"key":"10.1016\/j.jamda.2025.106028_bib15","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jamda.2025.106028_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciy866","article-title":"Clinical practice guidelines by the infectious diseases Society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza","volume":"68","author":"Uyeki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jamda.2025.106028_bib21","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.35077","article-title":"Nirmatrelvir or Molnupiravir use and severe outcomes from omicron infections","volume":"6","author":"Lin","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jamda.2025.106028_bib22","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1038\/s41467-021-22580-8","article-title":"Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the syrian hamster model","volume":"12","author":"Rosenke","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jamda.2025.106028_bib23","article-title":"A viroimmunologic model to characterize the antiviral effect of Molnupiravir in outpatients infected with SARS-CoV-2: implication for treatment duration","volume":"1","author":"Nguyen","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jamda.2025.106028_bib24","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1093\/jac\/dkab318","article-title":"Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase I, open-label, dose-escalating, randomized controlled study","volume":"76","author":"Khoo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jamda.2025.106028_bib25","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100044","article-title":"Randomized trial of Molnupiravir or placebo in patients hospitalized with Covid-19","volume":"1","author":"Arribas","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jamda.2025.106028_bib26","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1111\/cts.13602","article-title":"Assessment of pharmacokinetics, safety, and tolerability following twice-daily administration of molnupiravir for 10 days in healthy participants","volume":"16","author":"Iwamoto","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.jamda.2025.106028_bib27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s43441-020-00203-6","article-title":"FDA\u2019s benefit\u2013risk framework for human drugs and biologics: role in benefit\u2013risk assessment and analysis of use for drug approvals","volume":"55","author":"Lackey","year":"2021","journal-title":"Ther Innov Regul Sci"},{"key":"10.1016\/j.jamda.2025.106028_bib28","series-title":"Statpearls [Internet]","article-title":"Oseltamivir","author":"Sur","year":"2024"},{"key":"10.1016\/j.jamda.2025.106028_bib29","series-title":"Statpearls","article-title":"Ritonavir","author":"Talha","year":"2025"},{"key":"10.1016\/j.jamda.2025.106028_bib30","author":"Troy"},{"key":"10.1016\/j.jamda.2025.106028_bib33","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1001\/archinte.160.21.3252","article-title":"Are patients at veterans affairs medical centers sicker? A comparative analysis of health status and medical resource use","volume":"160","author":"Agha","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jamda.2025.106028_bib34","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1177\/0033354916676279","article-title":"Demographic, military, and health characteristics of VA health care users and nonusers who served in or during operation enduring freedom or operation Iraqi freedom, 2009-2011","volume":"131","author":"Dursa","year":"2016","journal-title":"Public Health Rep"},{"key":"10.1016\/j.jamda.2025.106028_bib35","doi-asserted-by":"crossref","first-page":"11656","DOI":"10.1021\/acs.jmedchem.4c01342","article-title":"Fixing the achilles heel of pfizer\u2019s paxlovid for COVID-19 treatment","volume":"67","author":"Brewitz","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.jamda.2025.106028_bib36","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14656566.2023.2193668","article-title":"VV116 as a potential treatment for COVID-19","volume":"24","author":"McCarthy","year":"2023","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861025005456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861025005456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:24:08Z","timestamp":1784013848000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861025005456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1525861025005456"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2025.106028","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Feasibility of Safe and Efficient Administration of COVID-19 Chemoprophylaxis to Nursing Home Residents","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2025.106028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of Post-Acute and Long-Term Care Medical Association.","name":"copyright","label":"Copyright"}],"article-number":"106028"}}